NCT03824964UnknownEarly Phase 1
An Observational Clinical Study on the Safety and Efficacy of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Allife Medical Science and Technology Co., Ltd.0 sites10 target enrollmentStarted: February 1, 2019Last updated:
Conditions
Trial Snapshot
- Phase
- Early Phase 1
- Sponsor
- Enrollment
- 10
- Primary Endpoint
- Occurrence of treatment related adverse events as assessed by CTCAE v4.0
Study Overview
Brief Summary
This is a single-centre, single-arm and open-label study to investigate the safety and efficacy of anti CD19/CD22 CAR NK cells in patients with relapsed refractory B cell lymphoma.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •CD19(+) CD22(+) B cell lymphoma confirmed by pathological immunohistochemistry or flow cytometry
- •Previously accepted ≥ first-line regimen chemotherapy
- •Unconditional acceptance of hematopoietic stem cell transplantation or recurrence after hematopoietic stem cell transplantation
- •Over 18 years old and under 70 years old
- •The expected survival period is more than 3 months.
- •Important organ function is satisfied: cardiac ultrasound indicates cardiac ejection fraction ≥50%, no abnormal electrocardiogram; blood oxygen saturation ≥90%; creatinine clearance ≥40 mL/min; ALT and AST≤3 times normal range, Total bilirubin ≤ 2.0 mg / dL;
- •Blood routine: Hgb≥80 g/L, ANC≥1×109/L, PLT≥50×109/L;
- •The pregnancy test for women of childbearing age must be negative; both men and women must agree to use effective contraception during the treatment period and for the following 1 year.
- •Measurable target lesion
Exclusion Criteria
- •Patients with extramedullary relapse
- •Burkitt's lymphoma/leukemia
- •Previously received gene product treatment, anti-CD19/anti-CD3 treatment, or any anti-CD19/CD22 treatment;
- •Liver and kidney function:
- •Total bilirubin > 2 x ULN (Gilbert Syndrome > 3 x ULN)
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 3 × ULN
- •Serum creatinine clearance >60 mL/min
- •Serological examination:
- •Absolute neutrophil count (ANC) <0.75x109/L
- •Platelet count (PLT) <50x109/L
- •Active hepatitis B (HBV-DNA > 1000 copies / mL), hepatitis C, or uncontrolled infection
- •GVHD ≥ 2 or anti-GVHD treatment
- •IM19 CAR NK cells received allogeneic cell therapy within 6 weeks before infusion, such as donor lymphocyte infusion;
- •Subject received the most recent treatment (release, chemotherapy, or other) less than 4 weeks
- •Active CNS disease (tumor cells in CSF, but < 5 WBCs/mL can be included);
- •Intracranial hypertension or unconsciousness; respiratory failure; diffuse vascular internal coagulation
- •Creatinine > 1.5 times normal upper limit or ALT / AST > 3 times normal upper limit or bilirubin > 2 times normal upper limit
- •New York Heart Association (NYHA) graded above or above
- •Uncontrollable diabetes
- •Suffering from other uncontrolled diseases, the researchers believe that it is not suitable for joining
- •Any situation that the investigator believes may increase the risk of the subject or interfere with the test results
Outcomes
Primary Outcomes
Occurrence of treatment related adverse events as assessed by CTCAE v4.0
Time Frame: 1 year
Defined as \>= Grade 3 signs/symptoms, laboratory toxicities, and clinical events) that are possibly, likely, or definitely related to study treatment.
Secondary Outcomes
No secondary outcomes reported
Investigators
Similar Trials
Unknown
Early Phase 1
Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell LymphomaRefractory B-Cell LymphomaNCT03824951Allife Medical Science and Technology Co., Ltd.10
Unknown
Early Phase 1
Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell LymphomaRefractory B-Cell LymphomaNCT03692767Allife Medical Science and Technology Co., Ltd.9
Unknown
Early Phase 1
Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell LymphomaRefractory B-Cell LymphomaNCT03690310Allife Medical Science and Technology Co., Ltd.9
Not yet recruiting
Phase 2
Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal CancerAdvanced Colorectal CancerNCT05364489The First Affiliated Hospital of Zhengzhou University20
Recruiting
Not Applicable
Radiotherapy Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of NSCLC Patients With Symptomatic Brain MetastasesNon-small Cell Lung Cancer MetastaticBrain MetastasesNCT05638425Xiangya Hospital of Central South University20